Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Bio-Gene Technology Ltd. ( (AU:BGT) ) is now available.
Bio-Gene Technology Limited has appointed experienced finance executive Drew Speedy as Chief Financial Officer and Company Secretary, effective 1 February 2026, replacing outgoing CFO and Company Secretary Edmond Tern. With more than two decades in senior finance and governance roles across ASX-listed and private companies and a background in financial reporting, corporate governance, capital raisings, M&A, IPOs and ASX compliance, Speedy will oversee the company’s financial stewardship and act as the primary contact with the ASX, bolstering Bio-Gene’s corporate capabilities as it advances its development and commercialisation strategy for its bio-insecticide portfolio.
The most recent analyst rating on (AU:BGT) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Bio-Gene Technology Ltd. stock, see the AU:BGT Stock Forecast page.
More about Bio-Gene Technology Ltd.
Bio-Gene Technology Limited is an Australian agtech development company focused on creating novel bio-insecticides to combat global insecticide resistance. Its products, based on a naturally occurring class of compounds, aim to control pests with minimal impact on human health and the environment and have applications across crop protection, grain storage, public health and consumer uses, positioning the company in markets seeking safer, nature-derived pest management solutions.
Average Trading Volume: 203,646
Technical Sentiment Signal: Buy
Current Market Cap: A$10.68M
For an in-depth examination of BGT stock, go to TipRanks’ Overview page.